We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stryker Launches Synchfix EVT for Flexible Syndesmotic Fixation
Read MoreHide Full Article
Key Takeaways
Stryker launched Synchfix EVT, a next-gen flexible fixation system for ankle syndesmotic injuries.
SYK's device simplifies deployment, supports single-handed use and improves OR efficiency.
Stryker's system is first approved for adolescents, expanding reach in ankle trauma care.
Stryker (SYK - Free Report) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in patients with syndesmotic injuries. The Synchfix EVT builds upon the company’s Synchfix platform, with targeted design modifications for simplifying deployment and reducing procedural steps compared to the prior-generation device.
Management emphasized that Synchfix EVT aligns with its objective of improving procedural efficiency for foot and ankle surgeons while maintaining a strong focus on patient outcomes and safety. The device reflects SYK’s continued investment in next-generation soft tissue solutions designed to streamline surgical workflows. Constant engagement and feedback from surgeons influenced the design of Synchfix EVT, leading to practical improvements in both the device and the surgical procedure.
Stryker will conduct interactive demonstrations of Synchfix EVT at the American College of Foot and Ankle Surgeons Annual Meeting to showcase the system’s capabilities.
Likely Trend of SYK Stock Following the News
Following the announcement, shares of SYK lost 0.9% at yesterday’s closing. Over the past six months, shares of the company have dropped 2.5% compared with the industry’s 12.3% decline. However, the S&P 500 has risen 8.1% during the same time frame.
In the long run, the launch strengthens Stryker’s Foot & Ankle portfolio by expanding its presence in the growing sports medicine and trauma market. The adolescent indication widens the addressable patient base and potential first-mover advantage, while the single-use, knotless and sterile design supports operating room efficiency. Visibility at the American College of Foot and Ankle Surgeons meeting should aid early commercialization efforts. Overall, the launch reinforces Stryker’s innovation cadence and may contribute to long-term revenue growth in its trauma portfolio.
SYK currently has a market capitalization of $147.23 billion.
Image Source: Zacks Investment Research
More on the Synchfix EVT
Synchfix EVT is designed as an all-in-one system that combines the suture tensioning tools with the implant instruments. It features a handle configuration that enables controlled, single-handed deployment during surgery. The device is built to enhance overall usability, featuring an ergonomic handle and a low-profile titanium medial implant.
Synchfix EVT is designed for the fixation of soft tissue and bone injuries in cases of ankle syndesmosis disruption, with or without ankle fractures. It can also be used alongside standard fracture hardware in Weber B, Weber C and Maisonneuve fracture patterns in both adult and adolescent patients.
It is the first flexible syndesmotic fixation device approved for use in adolescent patients, expanding clinical applicability and increasing the company’s reach into an underserved segment of ankle trauma care. The system has received the Red Dot Design Award, recognizing its innovative all-in-one implant and instrumentation that optimize syndesmotic fixation while improving procedural efficiency relative to the prior-generation system.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the trauma and extremities devices market is valued at $16.55 billion in 2026 and is expected to witness a CAGR of 5.2% through 2034.
Factors such as the increasing prevalence of orthopedic disorders and injuries, along with ongoing developments in less invasive surgical techniques like intramedullary nails and locking plate systems for faster healing and reduced soft tissue trauma, are enhancing the market expansions.
Other News
Stryker recently launched the T2 Alpha Humerus Nailing System, expanding its trauma portfolio with a streamlined solution for complex humeral fractures. Built on SOMA technology, the system enhances anatomical alignment and fixation stability while integrating with the existing T2 Alpha platform to improve workflow efficiency and hospital standardization.
Stryker announced the limited market release of the Mako RPS (Robotic Power System) for Total Knee, an intuitive handheld robotic solution that combines the company’s robotics expertise with its established power tool technologies, expanding the Mako platform into a new robotics segment. Compatible with the Triathlon Total Knee System, Mako RPS is designed for surgeons seeking robotic assistance while maintaining the familiarity of manual instruments. The system features intraoperative planning and a robotically guided saw with active adjustment technology that aligns cutting with the surgical plan while integrating seamlessly into existing workflows and the Q Guidance System.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Veracyte (VCYT - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.8% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Veracyte, currently carrying a Zacks Rank #2, reported third-quarter 2025 adjusted EPS of 51 cents, which surpassed the Zacks Consensus Estimate by 59.4%. Revenues of $131.8 million beat the Zacks Consensus Estimate by 5.5%.
VCYT has an estimated earnings recession rate of 3% for 2026 compared with the industry’s 16.8% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 45.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Stryker Launches Synchfix EVT for Flexible Syndesmotic Fixation
Key Takeaways
Stryker (SYK - Free Report) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in patients with syndesmotic injuries. The Synchfix EVT builds upon the company’s Synchfix platform, with targeted design modifications for simplifying deployment and reducing procedural steps compared to the prior-generation device.
Management emphasized that Synchfix EVT aligns with its objective of improving procedural efficiency for foot and ankle surgeons while maintaining a strong focus on patient outcomes and safety. The device reflects SYK’s continued investment in next-generation soft tissue solutions designed to streamline surgical workflows. Constant engagement and feedback from surgeons influenced the design of Synchfix EVT, leading to practical improvements in both the device and the surgical procedure.
Stryker will conduct interactive demonstrations of Synchfix EVT at the American College of Foot and Ankle Surgeons Annual Meeting to showcase the system’s capabilities.
Likely Trend of SYK Stock Following the News
Following the announcement, shares of SYK lost 0.9% at yesterday’s closing. Over the past six months, shares of the company have dropped 2.5% compared with the industry’s 12.3% decline. However, the S&P 500 has risen 8.1% during the same time frame.
In the long run, the launch strengthens Stryker’s Foot & Ankle portfolio by expanding its presence in the growing sports medicine and trauma market. The adolescent indication widens the addressable patient base and potential first-mover advantage, while the single-use, knotless and sterile design supports operating room efficiency. Visibility at the American College of Foot and Ankle Surgeons meeting should aid early commercialization efforts. Overall, the launch reinforces Stryker’s innovation cadence and may contribute to long-term revenue growth in its trauma portfolio.
SYK currently has a market capitalization of $147.23 billion.
Image Source: Zacks Investment Research
More on the Synchfix EVT
Synchfix EVT is designed as an all-in-one system that combines the suture tensioning tools with the implant instruments. It features a handle configuration that enables controlled, single-handed deployment during surgery. The device is built to enhance overall usability, featuring an ergonomic handle and a low-profile titanium medial implant.
Synchfix EVT is designed for the fixation of soft tissue and bone injuries in cases of ankle syndesmosis disruption, with or without ankle fractures. It can also be used alongside standard fracture hardware in Weber B, Weber C and Maisonneuve fracture patterns in both adult and adolescent patients.
It is the first flexible syndesmotic fixation device approved for use in adolescent patients, expanding clinical applicability and increasing the company’s reach into an underserved segment of ankle trauma care. The system has received the Red Dot Design Award, recognizing its innovative all-in-one implant and instrumentation that optimize syndesmotic fixation while improving procedural efficiency relative to the prior-generation system.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the trauma and extremities devices market is valued at $16.55 billion in 2026 and is expected to witness a CAGR of 5.2% through 2034.
Factors such as the increasing prevalence of orthopedic disorders and injuries, along with ongoing developments in less invasive surgical techniques like intramedullary nails and locking plate systems for faster healing and reduced soft tissue trauma, are enhancing the market expansions.
Other News
Stryker recently launched the T2 Alpha Humerus Nailing System, expanding its trauma portfolio with a streamlined solution for complex humeral fractures. Built on SOMA technology, the system enhances anatomical alignment and fixation stability while integrating with the existing T2 Alpha platform to improve workflow efficiency and hospital standardization.
Stryker announced the limited market release of the Mako RPS (Robotic Power System) for Total Knee, an intuitive handheld robotic solution that combines the company’s robotics expertise with its established power tool technologies, expanding the Mako platform into a new robotics segment. Compatible with the Triathlon Total Knee System, Mako RPS is designed for surgeons seeking robotic assistance while maintaining the familiarity of manual instruments. The system features intraoperative planning and a robotically guided saw with active adjustment technology that aligns cutting with the surgical plan while integrating seamlessly into existing workflows and the Q Guidance System.
Stryker Corporation Price
Stryker Corporation price | Stryker Corporation Quote
SYK’s Zacks Rank & Key Picks
Currently, SYK has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Veracyte (VCYT - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.8% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
Veracyte, currently carrying a Zacks Rank #2, reported third-quarter 2025 adjusted EPS of 51 cents, which surpassed the Zacks Consensus Estimate by 59.4%. Revenues of $131.8 million beat the Zacks Consensus Estimate by 5.5%.
VCYT has an estimated earnings recession rate of 3% for 2026 compared with the industry’s 16.8% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 45.1%.